TLE3 as a candidate biomarker of response to taxane therapy

INTRODUCTION: The addition of taxanes (Ts) to chemotherapeutic regimens has not demonstrated a consistent benefit in early-stage breast cancer. To date, no clinically relevant biomarkers that predict T response have been identified. METHODS: A dataset of immunohistochemistry stains in 411 patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Swati A, Hicks, David G, Watroba, Nancy L, Murekeyisoni, Christine, Hwang, Helena, Khoury, Thaer, Beck, Rodney A, Ring, Brian Z, Estopinal, Noel C, Schreeder, Marshall T, Seitz, Robert S, Ross, Douglas T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688945/
https://www.ncbi.nlm.nih.gov/pubmed/19309506
http://dx.doi.org/10.1186/bcr2241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2688945/
https://www.ncbi.nlm.nih.gov/pubmed/19309506
http://dx.doi.org/10.1186/bcr2241

Ejemplares similares